The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Treatment of vascular risk factors in patients with a diagnosis of Alzheimer’s disease: a systematic review
Abstract
BACKGROUND: Increasing evidence suggests vascular risk factors (VRF) play a role in the pathogenesis of Alzheimer's disease (AD). Epidemiological studies have found associations between VRF and risk of AD. Treating VRF in patients with AD offers a potential treatment option but ineffective treatments should be avoided in this group who are frequently on multiple medications and in whom compliance may be challenging. METHODS: Studies containing information on the treatment of VRF in patients with a diagnosis of AD were identified using a defined search strategy. Randomised controlled trials and observational studies were included. RESULTS: The pre-specified search strategy retrieved 11,992 abstract articles, and 25 papers including those identified on review of reference lists and reviews met the inclusion criteria. Of these, 11 were randomised controlled trials (RCTs) and 14 observational studies. Observational studies suggested that a VRF package and treatment of hypertension and statin therapy may be associated with improved outcome but these studies suffered from potential bias. The few RCTs performed were mostly small with short duration follow-up, and do not provide clear evidence either way. CONCLUSIONS: Observational data raises the possibility that treating VRF could alter the rate of decline in AD. However RCT data are not yet available to support this hypothesis and to alter clinical practice. RCTs in larger numbers of individuals with longer follow-up, ideally in the early stages of AD, are required to address this potentially important treatment question.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“randomized clinical trials have reported conflicting results on the efficacy of renin-angiotensin system inhibitors on AD progression, 14”
From Hypertension enhances A β -induced neurovascular dysfunction, promotes β -secretase activity, and leads to amyloidogenic processing of APP (2016) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
High-Dose Atorvastatin after Stroke or Transient Ischemic Attack
The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061894 · Cited by 2,887
Midlife blood pressure and dementia: the Honolulu–Asia aging study☆
Launer, L. J., Ross, G. W., Petrovitch, H., Masaki, K., Foley, D., White, L. R., & Havlik, R. J. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00096-8 · Cited by 1,008
Risner, M. E., Saunders, A. M., Altman, J. F. B., Ormandy, G. C., Craft, S., Foley, I. M., Zvartau-Hind, M. E., Hosford, D. A., Roses, A. D., & for the Rosiglitazone in Alzheimer's Disease Study Group (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500369 · Cited by 686
Vascular risk factors for Alzheimer’s disease:
Breteler, M. M. B. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(99)00110-4 · Cited by 664
Ghisletti, S., Huang, W., Ogawa, S., Pascual, G., Lin, M.-E., Willson, T. M., Rosenfeld, M. G., & Glass, C. K. (2007) · Molecular Cell · doi:10.1016/j.molcel.2006.11.022 · Cited by 561
Craft, S. (2007) · Current Alzheimer Research · doi:10.2174/156720507780362137 · Cited by 487
Li, N.-C., Lee, A., Whitmer, R. A., Kivipelto, M., Lawler, E., Kazis, L. E., & Wolozin, B. (2010) · BMJ · doi:10.1136/bmj.b5465 · Cited by 486
Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe
Feldman, H. H., Doody, R. S., Kivipelto, M., Sparks, D. L., Waters, D. D., Jones, R. W., Schwam, E., Schindler, R., Hey-Hadavi, J., DeMicco, D. A., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d6476a · Cited by 438
Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease
Sato, T., Hanyu, H., Hirao, K., Kanetaka, H., Sakurai, H., & Iwamoto, T. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.10.009 · Cited by 387
Gold, M., Alderton, C., Zvartau-Hind, M., Egginton, S., Saunders, A. M., Irizarry, M., Craft, S., Landreth, G., Linnamägi, Ü., & Sawchak, S. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000318845 · Cited by 361
Research works printed but not linked: 42
- Barreto Pde S: Alzheimer's disease: learning from the past, looking to the future. Am J Alzheimers Dis Other Demen. 2013, 28: 304-305. 10.1177/1533317513488926. · DOI
- Reitz C, Mayeux R: Alzheimer disease: Epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol. 2014, 88: 640-651. 10.1016/j.bcp.2013.12.024. · DOI · Paper page
- Toledo JB, Arnold SE, Raible K, Brettschneider J, Xie SX, Grossman M, Monsell SE, Kukull WA, Trojanowski JQ: Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. Brain. 2013, 136: 2697-2706. 10.1093/brain/awt188. · DOI · Paper page
- Connolly A, Campbell S, Gaehl E, Iliffe S, Drake R, Morris J, Martin H, Purandare N: Under-provision of medical care for vascular diseases for people with dementia in primary care: a cross-sectional review. Br J Gen Pract. 2013, 63: e88-e96. 10.3399/bjgp13X663046. · DOI
- Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM: Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology. 1999, 53: 1937-1942. 10.1212/WNL.53.9.1937. · DOI · Paper page
- Diomedi M, Misaggi G: Vascular contribution to Alzheimer disease: predictors of rapid progression. CNS Neurol Disord Drug Targets. 2013, 12: 532-537. 10.2174/1871527311312040015. · DOI
- Richard E, Kuiper R, Dijkgraaf MG, van Gool WA: Vascular care in patients with Alzheimer's disease with cerebrovascular lesions-a randomized clinical trial. J Am Geriatr Soc. 2009, 57: 797-805. 10.1111/j.1532-5415.2009.02217.x. · DOI
- Ohrui T, Tomita N, Sato-Nakagawa T, Matsui T, Maruyama M, Niwa K, Arai H, Sasaki H: Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. Neurology. 2004, 63: 1324-1325. 10.1212/01.WNL.0000140705.23869.E9. · DOI · Paper page
- Kume K, Hanyu H, Sakurai H, Takada Y, Onuma T, Iwamoto T: Effects of telmisartan on cognition and regional cerebral blood flow in hypertensive patients with Alzheimer’s disease. Geriatrics Gerontol Int. 2012, 12: 207-214. 10.1111/j.1447-0594.2011.00746.x. · DOI
- Balfour JA, Plosker GL: Rosiglitazone. Drugs. 1999, 57: 921-930. 10.2165/00003495-199957060-00007. · DOI · Paper page
- Strum JC, Shehee R, Virley D, Richardson J, Mattie M, Selley P, Ghosh S, Nock C, Saunders A, Roses A: Rosiglitazone induces mitochondrial biogenesis in mouse brain. J Alzheimers Dis. 2007, 11: 45-51. · DOI · Paper page
- Straus DS, Glass CK: Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol. 2007, 28: 551-558. 10.1016/j.it.2007.09.003. · DOI · Paper page
- Pedersen WA, McMillan PJ, Kulstad JJ, Leverenz JB, Craft S, Haynatzki GR: Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol. 2006, 199: 265-273. 10.1016/j.expneurol.2006.01.018. · DOI · Paper page
- Toledo EM, Inestrosa NC: Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1 mouse model of Alzheimer's disease. Mol Psychiatry. 2010, 15: 272-285. 10.1038/mp.2009.72. · DOI · Paper page
- Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, Fishel MA, Kulstad JJ, Green PS, Cook DG, Kahn SE, Keeling ML, Craft S: Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry. 2005, 13: 950-958.
- Hanyu H, Sato T, Kiuchi A, Sakurai H, Iwamoto T: Pioglitazone improved cognition in a pilot study on patients with Alzheimer's disease and mild cognitive impairment with diabetes mellitus. J Am Geriatr Soc. 2009, 57: 177-179. 10.1111/j.1532-5415.2009.02067.x. · DOI · Paper page
- Austen B, Frears E, Davies H: Cholesterol upregulates production of A[beta] 1-40 and 1-42 in transfected cells. Neurobiol Aging. 2000, 21: 254-10.1016/S0197-4580(00)83093-6. · doi:10.1016/s0197-4580(00)83093-6
- Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K: Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci USA. 1998, 95: 6460-6464. 10.1073/pnas.95.11.6460. · DOI · Paper page
- Sparks DL, Hunsaker JC, Scheff SW, Kryscio RJ, Henson JL, Markesbery WR: Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease. Neurobiol Aging. 1990, 11: 601-607. 10.1016/0197-4580(90)90024-T. · DOI · Paper page
- Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, Sambamurti K, Duff K, Pappolla MA: Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis. 2000, 7: 321-331. 10.1006/nbdi.2000.0304. · DOI · Paper page
- Sparks DL, Kuo YM, Roher A, Martin T, Lukas RJ: Alterations of Alzheimer's disease in the cholesterol-fed rabbit, including vascular inflammation: preliminary observations. Ann N Y Acad Sci. 2000, 903: 335-344. 10.1111/j.1749-6632.2000.tb06384.x. · DOI · Paper page
- Sparks DL, Petanceska S, Sabbagh M, Connor D, Soares H, Adler C, Lopez J, Ziolkowski C, Lochhead J, Browne P: Cholesterol, copper and Abeta in controls, MCI, AD and the AD cholesterol-lowering treatment trial (ADCLT). Curr Alzheimer Res. 2005, 2: 527-539. 10.2174/156720505774932296. · DOI
- Simons M, Schwarzler F, Lutjohann D, von Bergmann K, Beyreuther K, Dichgans J, Wormstall H, Hartmann T, Schulz JB: Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol. 2002, 52: 346-350. 10.1002/ana.10292. · DOI · Paper page
- Winblad B, Jelic V, Kershaw P, Amatniek J: Effects of statins on cognitive function in patients with Alzheimer's disease in galantamine clinical trials. Drugs Aging. 2007, 24: 57-61. 10.2165/00002512-200724010-00004. · DOI
- Rosenberg PB, Mielke MM, Tschanz J, Cook L, Corcoran C, Hayden KM, Norton M, Rabins PV, Green RC, Welsh-Bohmer KA, Breitner JC, Munger R, Lyketsos CG: Effects of cardiovascular medications on rate of functional decline in Alzheimer disease. Am J Geriatr Psychiatry. 2008, 16: 883-892. 10.1097/JGP.0b013e318181276a. · DOI
- Razay G, Williams J, King E, Smith AD, Wilcock G: Blood pressure, dementia and Alzheimer's disease: the OPTIMA longitudinal study. Dement Geriatr Cogn Disord. 2009, 28: 70-74. 10.1159/000230877. · DOI
- Duron E, Rigaud AS, Dubail D, Mehrabian S, Latour F, Seux ML, Hanon O: Effects of antihypertensive therapy on cognitive decline in Alzheimer's disease. Am J Hypertens. 2009, 22: 1020-1024. 10.1038/ajh.2009.119. · DOI
- Bellew KM, Pigeon JG, Stang PE, Fleischman W, Gardner RM, Baker WW: Hypertension and the rate of cognitive decline in patients with dementia of the Alzheimer type. Alzheimer Dis Assoc Disord. 2004, 18: 208-213.
- Hajjar IM, Keown M, Lewis P, Almor A: Angiotensin converting enzyme inhibitors and cognitive and functional decline in patients with Alzheimer's disease: an observational study. Am J Alzheimers Dis Other Demen. 2008, 23: 77-83. 10.1177/1533317507309803. · DOI
- Soto ME, van Kan GA, Nourhashemi F, Gillette-Guyonnet S, Cesari M, Cantet C, Rolland Y, Vellas B: Angiotensin-converting enzyme inhibitors and Alzheimer's disease progression in older adults: results from the Réseau sur la Maladie d'Alzheimer Français cohort. J Am Geriatr Soc. 2013, 61: 1482-1488. 10.1111/jgs.12415. · DOI
- Ellul J, Archer N, Foy CM, Poppe M, Boothby H, Nicholas H, Brown RG, Lovestone S: The effects of commonly prescribed drugs in patients with Alzheimer's disease on the rate of deterioration. J Neurol Neurosurg Psychiatry. 2007, 78: 233-239. 10.1136/jnnp.2006.104034. · DOI
- Kehoe PG, Davies NM, Martin RM, Ben-Shlomo Y: Associations of angiotensin targeting antihypertensive drugs with mortality and hospitalization in primary care patients with dementia. J Alzheimers Dis. 2013, 33: 999-1008. · DOI
- Plastino M, Fava A, Pirritano D, Cotronei P, Sacco N, Sperlì T, Spanò A, Gallo D, Mungari P, Consoli D, Bosco D: Effects of insulinic therapy on cognitive impairment in patients with Alzheimer disease and diabetes mellitus type-2. J Neurol Sci. 2010, 288: 112-116. 10.1016/j.jns.2009.09.022. · DOI
- Masse I, Bordet R, Deplanque D, Al Khedr A, Richard F, Libersa C, Pasquier F: Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2005, 76: 1624-1629. 10.1136/jnnp.2005.063388. · DOI
- Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM: Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy. 2003, 23: 871-880. 10.1592/phco.23.7.871.32720. · DOI · Paper page
- Padala KP, Padala PR, Potter JF: Statins: a case for drug withdrawal in patients with dementia. J Am Geriatr Soc. 2010, 58: 1214-1216. 10.1111/j.1532-5415.2010.02889.x. · DOI
- Muldoon MF, Barger SD, Ryan CM, Flory JD, Lehoczky JP, Matthews KA, Manuck SB: Effects of lovastatin on cognitive function and psychological well-being. Am J Med. 2000, 108: 538-546. 10.1016/S0002-9343(00)00353-3. · DOI · Paper page
- Muldoon MF, Ryan CM, Sereika SM, Flory JD, Manuck SB: Randomized trial of the effects of simvastatin on cognitive function in in hypercholesterolemic adults. Am J Med. 2004, 117: 823-829. 10.1016/j.amjmed.2004.07.041. · DOI · Paper page
- Schubert CC, Boustani M, Callahan CM, Perkins AJ, Carney CP, Fox C, Unverzagt F, Hui S, Hendrie HC: Comorbidity profile of dementia patients in primary care: are they sicker?. J Am Geriatr Soc. 2006, 54: 104-109. 10.1111/j.1532-5415.2005.00543.x. · DOI · Paper page
- Dhikav V, Singh P, Anand KS: Medication adherence survey of drugs useful in prevention of dementia of Alzheimer's type among Indian patients. Int Psychogeriatr. 2013, 25: 1409-1413. 10.1017/S1041610213000744. · DOI
- Blais L, Kettani FZ, Perreault S, Leroux JC, Forget A, Kergoat MJ: Adherence to cholinesterase inhibitors in patients with Alzheimer's disease. J Am Geriatr Soc. 2009, 57: 366-368. 10.1111/j.1532-5415.2009.02075.x. · doi:10.1111/j.1532-5415.2009.02075.x
- Roe CM, Anderson MJ, Spivack B: How many patients complete an adequate trial of donepezil?. Alzheimer Dis Assoc Disord. 2002, 16: 49-51. 10.1097/00002093-200201000-00008. · DOI
Cited by
Drug treatments in Alzheimer’s disease
Briggs, R., Kennelly, S. P., & O’Neill, D. (2016) · Clinical Medicine · doi:10.7861/clinmedicine.16-3-247 · Cited by 571
The neuropathology and cerebrovascular mechanisms of dementia
Raz, L., Knoefel, J., & Bhaskar, K. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.164 · Cited by 470
Daulatzai, M. A. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.23777 · Cited by 429
Functionality of sugars in foods and health
Clemens, R. A., Jones, J. M., Kern, M., Lee, S., Mayhew, E. J., Slavin, J. L., & Zivanovic, S. (2016) · Comprehensive Reviews in Food Science and Food Safety · doi:10.1111/1541-4337.12194 · Cited by 224
Alzheimer's Disease Puzzle: Delving into Pathogenesis Hypotheses
(2024) · aging and disease · doi:10.14336/ad.2023.0608 · Cited by 183
Metadata
- Authors
- Valenti, R., Pantoni, L., & Markus, H. S.
- Venue
- BMC Medicine
- Published
- 2014-11-11
- Volume
- 12
- Issue
- 1
- ISSN
- 1741-7015
- Cited by
- 51
- References
- 12
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of vascular risk factors in patients with a diagnosis of Alzheimer’s disease: a systematic review. https://app.cochat.ai/papers/10.1186/s12916-014-0160-z
- The paper
- Valenti, R., Pantoni, L., & Markus, H. S. (2014). Treatment of vascular risk factors in patients with a diagnosis of Alzheimer’s disease: a systematic review. BMC Medicine. https://doi.org/10.1186/s12916-014-0160-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.